Associate Director, Independent Medical Education
Novo Nordisk Inc.
Advocating Innovation in CME
Angelo Carter, PharmD is an innovator. Over the past 15 years he has worked to improve the health of literally hundreds of thousands of people. It doesn’t matter that patients with hypertension, heart failure, cardiometabolic issues, cancer, obesity, and diabetes may not know him. Through his work at Novartis, Bristol-Myers Squibb, and now, Novo Nordisk, he has enabled the education of tens of thousands of clinicians on breakthrough science and procedures that improves patient health.
One of the areas in which he has truly thrived is finding unique opportunities for CME. Now, you may think CME is just cookie cutter stuff. While there is a place for more standard learning interventions, Angelo understands that the customer experience is key. So instead of always sticking with the standard CME, he seeks out strategies that shape the experience to each physician.
Angelo was the first educator to use Sequence to tailor educational content in hypertension. This novel platform created 30,000 unique courses for 30,000 unique clinicians. According to a study by Temple University, that personalized program was 7x more engaging than standard CME. He then leveraged the data from that experience to improve subsequent educational interventions, making them more effective and specific to needs based on certain geographies or among clinicians in different age groups.
Today, Angelo still craves real-world feedback. He was one of the first educators to support ZEN, a unique platform that gathers data about individual clinician needs and interests as they relate to the practice of medicine. At SITC, the Society for Immunotherapy and Cancer, in November 2015, more than 800 oncologists used ZEN to navigate sessions, posters, and abstracts; connect with colleagues; and, yes, learn. This real-time data provides significant insights into the topics and types of sessions this physician community needs to continue to advance the care of their patients; allowing Angelo to deliver more targeted and innovative education.
And when Angelo seeks innovation, people get better. How many of us can make that claim?